Moderna (MRNA) has achieved a significant milestone in its oncology pipeline with positive Phase 3 data for Intismeran autogene, a combination therapy developed with Merck. The trial demonstrated a 42% relative reduction in the risk of relapse or death for melanoma patients compared to standard care, validating the efficacy of the mRNA technology in cancer treatment. Despite this clinical breakthrough, the article argues that Moderna's current stock price of approximately $221 is significantly overvalued. Analysts suggest a working valuation of around $60 per share, implying a potential 73% downside from current levels. This discrepancy exists because the market appears to be pricing in optimistic future scenarios that may not yet be supported by the company's financial reality. The primary concerns driving the bearish sentiment are Moderna's persistent cash burn and limited near-term product launches outside of its oncology efforts. While the pipeline optimism is reflected in the high current valuation, the lack of immediate revenue growth from new products creates a wide gap between the stock price and what discounted cash flow models justify under more conservative assumptions.